• SENSEX
    NIFTY 50
Business

Gilead to buy cancer drugmaker Immunomedics for $21 billion

Updated : September 14, 2020 10:41 AM IST

The transaction is expected to close in the fourth quarter of 2020, the companies said.
The acquisition of Immunomedics is the latest of the several Gilead inked this year with the aim of expanding its oncology portfolio.
Gilead to buy cancer drugmaker Immunomedics for $21 billion

You May Also Like

Live TV

recommended for you

Advertisement